Aker BioMarine was recently informed that LYSOVETATM, the company's innovative
brain and eye health ingredient derived from krill, has received the necessary
regulatory approval for commercial launch as a dietary supplement in the US. 

LYSOVETATM is a dietary supplement featuring essential nutrients such as choline
and Omega 3 in the form of Lysophosphatidylcholine (LPC). LPC is a molecule with
the unique ability to be transported across the blood brain barrier containing
important nutrients for the brain and eye health.

The company is working with well-established brands to drive commercial
opportunities for LYSOVETATM. Launching a new ingredient involves long processes,
starting from client testing & trial and going all the way to retailer sales &
marketing efforts, but the company has an ambition to have first sales of
consumer products during 2024. 

Production of LYSOVETATM is done in the company's manufacturing plant in Houston,
which has a dedicated production line up and running. 

For further information, please contact 
Christopher Robin Vinter, Investor Relations
Mobile: +47 911 60 820
Email:  Christopher.vinter@akerbiomarine.com  

About Aker BioMarine:
Aker BioMarine is an Antarctic krill-harvesting company and leading biotech
innovator developing krill-derived products for pharma, consumer health and
wellness as well as animal nutrition. The company has a strong position in its
industry and is the world's leading supplier of krill, the natural, powerful and
health promoting source of nutrients from the pristine waters of Antarctica.
Aker BioMarine is listed on Oslo Stock Exchange (AKBM). More information is
available at www.akerbiomarine.com.